Publication of Prospectus

Genus PLC
07 November 2007




For Immediate Release                                            7 November 2007


                                        Genus plc
                               ('Genus' or 'the Company')

                                Publication of Prospectus
                                Move to the Official List

Genus plc (AIM: GNS), a world leading animal genetics company, is pleased to
announce that it has published its prospectus in connection with the proposed
listing of its entire issued ordinary share capital on the Official List of the
UK Listing Authority and admission to trading on the London Stock Exchange's
market for listed securities ('Admission').

It is expected that Admission will become effective and that dealings on the
London Stock Exchange's main market will commence at 8.00 am on Monday 12
November 2007.  Trading in the Company's ordinary shares on AIM will be
cancelled simultaneously.

The Company's stock code will continue to be LSE: GNS (GNS.L for Reuters and GNS
LN for Bloomberg) and there will be 59,204,190 ordinary shares in issue on
Admission.

Copies of the prospectus are available from the 'Investors' section of the
Company's website at www.genusplc.com.  The prospectus has also been submitted
to the UKLA's Document Viewing Facility situated at: Financial Services
Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.



For further information, please contact:

Genus plc                                                 Tel: [phone]
Richard Wood, Chief Executive
Martin Boden, Finance Director


Landsbanki Securities (UK) Limited                        Tel: [phone]
Nominated Adviser & Joint Broker
Shaun Dobson


Buchanan Communications                                   Tel: [phone]
Charles Ryland / Suzanne Brocks







About Genus



Genus creates and sells added value products for livestock farming and food
producers by creating advances to animal breeding through biotechnology.  Its
non-Genetically Modified Organism (GMO) technology is applicable across all
livestock species but is only commercialised by Genus in the bovine and porcine
farming sectors.



Genus' worldwide sales are made in seventy countries under the trade marks 'ABS'
(dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production.  Customers
produce offspring with greater production efficiency, milk and meat output and
quality and use these to supply the global dairy and meat supply chain.



Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.



Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on five continents, with research laboratories located in Madison, USA.


                      This information is provided by RNS
            The company news service from the London Stock Exchange